Overview

3VM for Treatment of Chronic Osteoarthritis Knee Pain

Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
A double-blind, placebo-controlled, randomized dose ranging study for the use of 3VM1001 Cream, 2g three times daily, 3g three times daily, or 3g four times daily for treatment of chronic pain associated with osteoarthritis of the knee compared to inactive placebo.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
CDA Research Group, Inc.